ES2052478T1 - RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS. - Google Patents
RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS.Info
- Publication number
- ES2052478T1 ES2052478T1 ES91900526T ES91900526T ES2052478T1 ES 2052478 T1 ES2052478 T1 ES 2052478T1 ES 91900526 T ES91900526 T ES 91900526T ES 91900526 T ES91900526 T ES 91900526T ES 2052478 T1 ES2052478 T1 ES 2052478T1
- Authority
- ES
- Spain
- Prior art keywords
- hiv
- particles
- recombinants
- reproduction
- possibility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title abstract 6
- 230000001177 retroviral effect Effects 0.000 title abstract 4
- 230000000840 anti-viral effect Effects 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 230000000877 morphologic effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 229940124551 recombinant vaccine Drugs 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- USXVMPAWZOOYDE-HGUQNLGYSA-N trengestone Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 USXVMPAWZOOYDE-HGUQNLGYSA-N 0.000 abstract 1
- 229950003256 trengestone Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE DESCRIBEN PARTICULAS RETROVIRALES CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION QUE TIENEN CARACTERISTICAS ESTRUCTURALES, MORFOLOGICAS E INMUNOLOGICAS MUY SIMILARES A LAS DE LOS RETROVIRUS HUMANOS NATIVOS. EL METODO DE LA INVENCION CONSISTE EN LA COEXPRESION DE UN NUCLEO RETROVIRAL MADURO Y DE PROTEINAS ESTRUCTURALES ENVOLVENTES EN CELULAS HUESPEDES DE MAMIFEROS DE MODO QUE LAS PROTEINAS RETROVIRALES EXPRESADAS SE ASOCIAN EN PARTICULAS RETROVIRALES DE BROTE UNIDAS. EN UNA PUESTA EN PRACTICA PARTICULAR DE LA INVENCION, LAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION SE PRODUCEN A BASE DE COINFECTAR CELULAS HUESPEDES DE MAMIFEROS CON UN VIRUS DE VACUNA RECOMBINANTE QUE LLEVA LA PORCION DEL VIRUS DE INMUNODEFICIENCIA HUMANA TIPO Q (VIH-1) Y GENES DE PROTEASA Y UN VIRUS DE VACUNA RECOMBINANTE QUE LLEVA EL GEN ENVOLVENTE DEL VIH-1. ESTAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION TIENEN UNAS CARACTERISTICAS INMUNOLOGICAS Y MORFOLOGICAS MUY PARECIDAS A LAS DEL VIH-1 NATIVO, SON CAPACES DE BLOQUEAR LA INFECTIVIDAD DEL VIH VIVO IN VITRO Y SON MUY INMUNOGENICAS IN VIVO. LAS PARTICULAS DE VIH-1 CONVERTIDAS EN RECOMBINANTES SIN POSIBILIDAD DE REPRODUCCION DE LA INVENCION SE PUEDEN UTILIZAR COMO AGENTES ANTIVIRALES Y COMO INMUNOGENES EN FORMULAS PARA VACUNAS EFECTIVAS PARA INHIBIR O PREVENIR LA INFECCION POR VIH Y/O EL DESARROLLO DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA.RETROVIRAL PARTICLES CONVERTED IN RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION ARE DESCRIBED, HAVING STRUCTURAL, MORPHOLOGICAL AND IMMUNOLOGICAL CHARACTERISTICS VERY SIMILAR TO THOSE OF NATIVE HUMAN RETROVIRUSES. THE METHOD OF THE INVENTION CONSISTS OF THE COEXPRESSION OF A MATURE RETROVIRAL NUCLEUS AND OF ENVELOPE STRUCTURAL PROTEINS IN MAMMAL HOSPITAL CELLS SO THAT THE EXPRESSED RETROVIRAL PROTEINS ARE ASSOCIATED IN RETROID PARTICLES. IN A PARTICULAR PRACTICE OF THE INVENTION, THE HIV-1 PARTICLES CONVERTED IN RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION ARE PRODUCED BASED ON COINFECTING CELLS HOSPED BY MAMMALS WITH A RECOMBINANT VACCINE VACCINE VIRUSED BY THE VODUNCIATION OF VIVUNIUM (HIV-1) AND PROTEASE GENES AND A RECOMBINANT VACCINE VIRUS CARRYING THE ENVELOPING GENE OF HIV-1. THESE PARTICLES OF HIV-1 BECOMING RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION HAVE VERY IMMUNOLOGICAL AND MORPHOLOGICAL CHARACTERISTICS OF NATIVE HIV-1, ARE CAPABLE OF BLOCKING THE INFECTIVITY OF LIVING HIV IN VITRO AND ARE VERY INOUGH. PARTICLES OF HIV-1 BECOMING RECOMBINANTS WITH NO POSSIBILITY OF REPRODUCTION OF THE INVENTION MAY BE USED AS ANTIVIRAL AGENTS AND AS IMMUNOGENES IN EFFECTIVE VACCINES FOR INHIBITING OR PREVENTING DEVELOPMENT OF HIV INFECTION AND / OR DEVELOPMENT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2052478T1 true ES2052478T1 (en) | 1994-07-16 |
Family
ID=23743729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES91900526T Pending ES2052478T1 (en) | 1989-11-20 | 1990-11-20 | RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0502105A4 (en) |
| JP (1) | JPH05503629A (en) |
| KR (1) | KR920703639A (en) |
| AU (1) | AU636944B2 (en) |
| CA (1) | CA2068713A1 (en) |
| ES (1) | ES2052478T1 (en) |
| FI (1) | FI922277A0 (en) |
| GR (1) | GR930300005T1 (en) |
| HU (1) | HUT60506A (en) |
| NO (1) | NO921969L (en) |
| OA (1) | OA09698A (en) |
| TW (1) | TW216446B (en) |
| WO (1) | WO1991007425A1 (en) |
| ZA (1) | ZA909302B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3034025B2 (en) * | 1989-06-01 | 2000-04-17 | アプライド・バイオテクノロジー・インコーポレーテツド | Self-assembled deficient non-self-replicating virions |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| DE4124817A1 (en) * | 1991-07-26 | 1993-01-28 | Basf Ag | AQUEOUS POLYMER DISPERSIONS |
| ATE219520T1 (en) * | 1991-11-08 | 2002-07-15 | Upjohn Co | VACCINE AGAINST FELINE LEUKEMIA VIRUS |
| JPH07505412A (en) * | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Induction of CTL responses |
| ES2320883T3 (en) * | 1993-01-26 | 2009-05-29 | The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF GENETIC MATERIAL. |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| ATE302854T1 (en) | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF GENETIC MATERIAL |
| GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
| US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| CN1185811A (en) * | 1995-03-31 | 1998-06-24 | H·沃尔夫 | Antigen presentation system on retrovirus-like particles |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| WO2000039303A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Modified hiv env polypeptides |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| WO2001092470A2 (en) | 2000-03-02 | 2001-12-06 | Emory University | Dna expression vectors and methods of use |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| AU2002252199B2 (en) | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AP2013007166A0 (en) | 2011-04-06 | 2013-10-31 | Univ Paris Descartes Inst De Rech Pour Le Dev Ird | Pharmaceutical compositions for preventing and/or treating an HIV disease in humans |
| US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA55321A (en) * | 2019-03-15 | 2022-01-19 | Modernatx Inc | RNA VACCINES AGAINST HIV |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| JPH02203783A (en) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | Cloned human t cell forming non-virulent aids virus having antigenicity |
| JP3140757B2 (en) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | Packaging defective HIV provirus, cell lines and uses thereof |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| WO1991005860A1 (en) * | 1989-10-16 | 1991-05-02 | Whitehead Institute For Biomedical Research | Non-infectious hiv-1 particles and uses therefor |
-
1990
- 1990-11-20 HU HU9201659A patent/HUT60506A/en unknown
- 1990-11-20 KR KR1019920701189A patent/KR920703639A/en not_active Application Discontinuation
- 1990-11-20 CA CA002068713A patent/CA2068713A1/en not_active Abandoned
- 1990-11-20 AU AU69055/91A patent/AU636944B2/en not_active Ceased
- 1990-11-20 JP JP3501082A patent/JPH05503629A/en active Pending
- 1990-11-20 ZA ZA909302A patent/ZA909302B/en unknown
- 1990-11-20 ES ES91900526T patent/ES2052478T1/en active Pending
- 1990-11-20 EP EP19910900526 patent/EP0502105A4/en not_active Withdrawn
- 1990-11-20 WO PCT/US1990/006798 patent/WO1991007425A1/en not_active Application Discontinuation
-
1991
- 1991-01-12 TW TW080100246A patent/TW216446B/zh active
-
1992
- 1992-05-19 NO NO92921969A patent/NO921969L/en unknown
- 1992-05-19 OA OA60209A patent/OA09698A/en unknown
- 1992-05-19 FI FI922277A patent/FI922277A0/en not_active Application Discontinuation
-
1993
- 1993-04-28 GR GR930300005T patent/GR930300005T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0502105A1 (en) | 1992-09-09 |
| ZA909302B (en) | 1991-09-25 |
| HU9201659D0 (en) | 1992-08-28 |
| NO921969D0 (en) | 1992-05-19 |
| OA09698A (en) | 1993-08-30 |
| NO921969L (en) | 1992-06-26 |
| EP0502105A4 (en) | 1993-02-24 |
| FI922277A (en) | 1992-05-19 |
| TW216446B (en) | 1993-11-21 |
| WO1991007425A1 (en) | 1991-05-30 |
| FI922277A0 (en) | 1992-05-19 |
| GR930300005T1 (en) | 1993-04-28 |
| CA2068713A1 (en) | 1991-05-21 |
| HUT60506A (en) | 1992-09-28 |
| KR920703639A (en) | 1992-12-18 |
| JPH05503629A (en) | 1993-06-17 |
| AU636944B2 (en) | 1993-05-13 |
| AU6905591A (en) | 1991-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2052478T1 (en) | RECOMBINANTLY PRODUCED NON-REPLICATION RETROVIRAL PARTICLES USED AS ANTIVIRAL AND IMMUNOGENOUS AGENTS. | |
| ES2061500T5 (en) | DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE. | |
| Karacostas et al. | Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. | |
| ATE187983T1 (en) | RECOMBINANT RETROVIRUSES | |
| DK513388D0 (en) | PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT | |
| WO1991002805A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
| Weger-Lucarelli et al. | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice | |
| ES2060646T3 (en) | HYBRID RNA VIRUSES. | |
| ES2070997T3 (en) | RECOMBINANT HERPES VIRUSES OF TURKEYS AND LIVING VECTOR VACCINES DERIVED FROM THEM. | |
| ES2134197T3 (en) | VACCINES AGAINST HERPES SIMPLEX VP16 VIRUSES. | |
| ES2140418T3 (en) | CHEMICAL FLAVIVIRUS AND / OR RESTRICTED GROWTH FLAVIVIRUS. | |
| AR003135A1 (en) | RECOMBINANT BACULOVIRUSES, A VACCINE THAT CONTAINS THEM, AND THE USE OF THE SAME TO PREPARE A VACCINE USEFUL TO AVOID OR DECREASE THE DISEASE CAUSED BY FELINE IMMUNODEFICIENCY VIRUSES. | |
| ES2056565T3 (en) | RECOMBINANT VIRUSES OF MAREK'S DISEASE. | |
| UY24367A1 (en) | TUMOR VACCINES AND PRODUCTION PROCEDURE | |
| ES2095241T3 (en) | OLIGONUCLEOTIDIC SEQUENCES FOR AMPLIFICATION OF THE GENOME OF RETROVIRUSES OF THE HIV-2 AND SIV TYPE, AND ITS APPLICATIONS TO THE IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES. | |
| ES2061603T3 (en) | VIRAL MUTANTS OF INFECTIOUS BOVINE RHINOTRACHEITIS, VACCINES THAT CONTAIN THEM, METHODS FOR THE PRODUCTION OF THE SAME AND METHODS FOR THE USE OF THE SAME. | |
| MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
| ES2195994T3 (en) | RECEIVING VIRUS OF MAREK'S DISEASE, THIS PREPARATION PROCEDURE; AND VACCINE THAT CONTAINS IT. | |
| DK76688A (en) | VACCINE CONTAINING F-PROTEIN FROM AIDS VIRUS | |
| TR200102168T2 (en) | BHV-1 gene deleted virus vaccine. | |
| DK631387A (en) | viral vector | |
| WO2022035860A3 (en) | Replication-competent adenovirus type 4-hiv env vaccines and their use | |
| WO2022147891A1 (en) | Cochlear outer hair cell regenerated by ectopic joint overexpression of atoh1 and ikzf2 and application thereof | |
| Condreay et al. | Emerging Considerations in Virus‐Based Gene Transfer Systems | |
| DK284389D0 (en) | PRECURSOR ANTIGENES |